Kura Oncology Inc (NASDAQ:KURA) – Equities researchers at Oppenheimer increased their FY2019 EPS estimates for Kura Oncology in a research report issued on Monday, November 5th. Oppenheimer analyst L. Cann now forecasts that the company will earn ($2.73) per share for the year, up from their previous forecast of ($2.95). Oppenheimer also issued estimates for Kura Oncology’s FY2022 earnings at $12.98 EPS.
Other equities research analysts also recently issued research reports about the stock. Cowen reaffirmed a “buy” rating on shares of Kura Oncology in a research report on Monday, October 22nd. HC Wainwright reaffirmed a “buy” rating and set a $31.00 price objective on shares of Kura Oncology in a research report on Monday, October 22nd. ValuEngine downgraded shares of Kura Oncology from a “strong-buy” rating to a “buy” rating in a research report on Friday, October 19th. Zacks Investment Research raised shares of Kura Oncology from a “sell” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Tuesday, October 16th. Finally, BidaskClub raised shares of Kura Oncology from a “hold” rating to a “buy” rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating and eight have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $27.29.
Shares of NASDAQ:KURA opened at $11.99 on Thursday. The company has a quick ratio of 10.22, a current ratio of 14.76 and a debt-to-equity ratio of 0.02. Kura Oncology has a fifty-two week low of $10.20 and a fifty-two week high of $24.02. The stock has a market cap of $459.87 million, a P/E ratio of -7.89 and a beta of 4.39.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.01.
Large investors have recently made changes to their positions in the stock. Voya Investment Management LLC bought a new stake in shares of Kura Oncology during the 2nd quarter valued at about $187,000. Los Angeles Capital Management & Equity Research Inc. bought a new position in Kura Oncology in the 2nd quarter worth about $218,000. Trexquant Investment LP bought a new position in Kura Oncology in the 3rd quarter worth about $217,000. BB&T Securities LLC bought a new position in Kura Oncology in the 2nd quarter worth about $291,000. Finally, Bank of America Corp DE grew its position in Kura Oncology by 327.1% in the 2nd quarter. Bank of America Corp DE now owns 17,729 shares of the company’s stock worth $323,000 after purchasing an additional 13,578 shares during the last quarter. 77.28% of the stock is owned by institutional investors and hedge funds.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
See Also: Beta
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.